Assembly Biosciences, Inc.
ASMB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001426800
In the last 90 days, Assembly Biosciences, Inc. insiders filed 0 open-market purchases and 4 sales; 93 institutions reported holding it in 13F filings for Q2 2026, worth $514.8M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 9, 2026
- $443.7M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $237.6K in total
- 4
- 13F holdersQ2 2026, +18 vs. previous quarter
- 93
- 13F valueReported value at the end of Q2 2026
- $514.8M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $72.3M
- +153.5% year over year
- Net income, FY2025
- -$6.12M
- No comparable prior period
- Free cash flow, FY2025
- -$41.2M
- No comparable prior period
- Revenue, Q2 FY2026
- $13.4M
- +38.9% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $6.12M (8.5% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 15, 2026.
- Short interest
- 2.91M
- Shares sold short
- Change
- +91.1K
- +3.2% vs. previous
- Days to cover
- 11.07
- At average daily volume
Superinvestors holding ASMB, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding ASMB at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Assembly Biosciences, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 3, 2026 (view filing)4:50 PM ET | Nov 2 | 1 day | Bjorkquist Jeanette MPFO and PAO | SSale | −727 | $19.62 | −$14.3K | −4.0%17.7K after | 2 lots |
| Nov 3, 2026 (view filing)4:45 PM ET | Nov 2 | 1 day | White Nicole SChief Manufacturing Officer | SSale | −2.59K | $19.62 | −$50.9K | −4.2%59.3K after | 2 lots |
| Nov 3, 2026 (view filing)4:35 PM ET | Nov 2 | 1 day | Gaggar AnujChief Medical Officer | SSale | −2.59K | $19.62 | −$50.9K | −4.6%53.8K after | 2 lots |
| Nov 3, 2026 (view filing)4:30 PM ET | Nov 2 | 1 day | Okazaki Jason ACEO and President | SSale | −6.20K | $19.62 | −$121.7K | −3.1%195.5K after | 2 lots |
| Jun 18, 2026 (view filing) | Jun 17 | 1 day | Bjorkquist Jeanette MPFO and PAO | SSale | −29 | $23.25 | −$674.25 | −0.2%14.6K after | |
| Mar 31, 2026 (view filing) | Mar 30 | 1 day | Bjorkquist Jeanette MPFO and PAO | SSale | −328 | $26.69 | −$8.75K | −2.9%11.1K after | 2 lots |
| Mar 31, 2026 (view filing) | Mar 30 | 1 day | White Nicole SChief Manufacturing Officer | SSale | −197 | $26.69 | −$5.26K | −0.5%37.5K after | 2 lots |
| Oct 3, 2025 (view filing) | Aug 8 | 56 daysLate | Gilead Sciences, Inc.10% Owner | PPurchase | +2.30M | – | – | +103.9%4.51M after | |
| Oct 3, 2025 (view filing) | Aug 8 | 56 daysLate | Gilead Sciences, Inc.10% Owner | PPurchase | +2.30M | – | – | –1.15M after | Derivative2 lots |
| Apr 15, 2025 (view filing) | Mar 31 | 15 daysLate | McHutchison John GDirector | SSale | −757 | $9.85 | −$7.46K | −4.0%18.3K after |
Top 10 13F holders, Q2 2026
See all 93 holdersThe largest institutional positions in Assembly Biosciences, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | 4,977,089 | $136.8M | 8.30% | +471,698+10.5% | Added |
| Farallon Capital Management, L.L.C. | 1,604,590 | $44.1M | 0.26% | +377,000+30.7% | Added |
| Paradigm Biocapital Advisors LP | 1,553,748 | $42.7M | 0.80% | +888,497+133.6% | Added |
| Commodore Capital LP | 1,415,000 | $38.9M | 2.32% | +415,000+41.5% | Added |
| Ra Capital Management, L.P. | 1,020,410 | $28.0M | 0.24% | 00.0% | Unchanged |
| Jupiter Topco LLC | 849,309 | $23.4M | 0.01% | +849,309 | New |
| BlackRock, Inc. | 766,819 | $21.1M | 0.00% | +564,076+278.2% | Added |
| Parkman Healthcare Partners LLC | 721,181 | $19.8M | 2.04% | +309,954+75.4% | Added |
| Vanguard Capital Management LLC | 558,942 | $15.4M | 0.00% | +68,495+14.0% | Added |
| Point72 Asset Management, L.P. | 460,593 | $12.7M | 0.02% | +116,488+33.9% | Added |
Holders of 5% or more of ASMB
See all 7 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Assembly Biosciences, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. | 13D/A | 25.10%4.98M shares | −3.90 ppfrom 29.00% | Oct 25, 20235 filings | May 27, 2026 | SEC |
| Commodore Capital LP | 13G | 9.90%1.62M shares | New | Aug 15, 20251 filing | Aug 15, 2025 | SEC |
| Ra Capital Management, L.P. | 13G | 9.50%1.53M shares | New | Aug 18, 20251 filing | Aug 18, 2025 | SEC |
| Farallon Capital Management, L.L.C. | 13G/A | 8.10%1.60M shares | – | Aug 4, 20261 filing | Aug 4, 2026 | SEC |
| Paradigm Biocapital Advisors LP | 13G/A | 7.80%1.55M shares | +2.40 ppfrom 5.40% | May 11, 20262 filings | Aug 14, 2026 | SEC |
Politician trades
All politician trades in ASMB1 member of Congress reported 2 trades in Assembly Biosciences, Inc. since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Feb 17, 2021 |  Chris Jacobs House · NY | Sell | $1K-$15K |
| Feb 10, 2021 | Chris Jacobs House · NY | Buy | $1K-$15K |
House · NY · Feb 17, 2021
Sell$1K-$15K
House · NY · Feb 10, 2021
Buy$1K-$15K